Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

November 10, 2026

Study Completion Date

November 10, 2027

Conditions

Dermatomyositis, JuvenileDermatomyositis

Interventions

DRUG

Anti-CD19 UCAR-T cells

A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.

Trial Locations (1)

RECRUITING

Children's Hospital Zhejiang University School of Medicine, Hangzhou, zhejiang, Hangzhou

All Listed Sponsors

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY